GlassScriptPhysician profile
Daniel K Elieff
NPI 1891778163
$564.66
in general payments reported to CMS, 2019-2025
10 companies · $79.07 in 2025
The $79.07 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.81 · 2022: $15.00 · 2023: $92.88 · 2024: $365 · 2025: $79.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.35 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $203.19 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $146.22 | 2024 | Tremfya |
| Kyowa Kirin, INC. | $42.25 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.18 | 2023-2024 | Spevigo |
| Genzyme Corporation | $34.88 | 2024 | |
| Dermavant Sciences, INC. | $28.54 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $20.79 | 2024 | Zoryve |
| Ucb, INC. | $19.73 | 2024 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $17.07 | 2023 | |
| Abbvie INC. | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Elieff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.